Novo Nordisk and Embark seek new therapies to tackle obesity

Embark Biotech and Novo Nordisk (NOV: N) have joined forces in a new collaboration to develop treatments for obesity and associated metabolic pathologies.

The project will focus on therapies that address these conditions through mechanisms that increase energy expenditure, leveraging the research platform of Embark Biotech, a recent spin-out from the Center for Basic Metabolic Research at the University of Copenhagen.

The firms think that the addition of energy expenditure drugs could make a meaningful difference in the treatment of obesity.